

Special Issue

Recent Developments of Vaccines in Cancer Immunotherapy

Message from the Guest Editors

Cancer vaccines have emerged as a promising modality in the evolving landscape of immuno-oncology. While therapeutic cancer vaccines have historically faced challenges in demonstrating clinical efficacy, recent advancements in vaccine design, delivery platforms, and antigen discovery are revitalizing the field. Key topics include novel vaccine platforms such as mRNA-based technologies, neoantigen-targeted approaches, and personalized vaccines tailored to individual tumor profiles. We also explore synergistic strategies combining vaccines with immune checkpoint inhibitors and other immunomodulatory agents in order to overcome immune resistance. Additionally, this Special Issue addresses critical translational challenges, including biomarker development, optimal patient selection, and trial design. By presenting a comprehensive overview of recent breakthroughs—from preclinical innovations to clinical applications—this collection aims to inform researchers, clinicians, and stakeholders of the immense potential and ongoing hurdles in leveraging vaccines for cancer treatment.

Guest Editors

Dr. Dmitrii Shek

Blacktown Clinical School, Western Sydney University, Marcel Crescent, Sydney, NSW 2148, Australia

Prof. Dr. Haval Shirwan

Department of Microbiology and Immunology, University of Missouri, Columbia, SC, USA

Deadline for manuscript submissions

1 July 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/251633

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).